Pacylex

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients. First clinical patient dosed at Cross Cancer Institute, Edmonton.

Read More

Recent News

Pacylex

Pacylex Pharmaceuticals Closes Series A Funding to Advance Oncology Program into the Clinic

Read More

Pacylex

Pacylex CEO Michael Weickert named a CEO To Watch

Read More

Pacylex

Health Canada Approves PCLX-001 Phase I Clinical Trial

Read More
Follow Pacylex